Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20986811 | 0.71 | RIPK1 (0.33) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL23573048 | 0.71 | RIPK1 (0.33) | — | |
| SCHEMBL28594150 | 0.70 | POLB (0.35) | POLB | |
| SCHEMBL2456121 | 0.69 | RIPK1 (0.30) | — | |
| SCHEMBL2330612 | 0.68 | HPGD (0.38) | HPGDGAAALDH1A1 | |
| SCHEMBL18783555 | 0.68 | ALDH1A1 (0.33) | POLBALDH1A1 | |
| SCHEMBL31518814 | 0.66 | HPGD (0.58) | HPGDGAALIPEPOLBALDH1A1 | |
| SCHEMBL75611 | 0.66 | HPGD (0.58) | HPGDGAALIPEPOLBALDH1A1 | |
| SCHEMBL9162112 | 0.66 | HPGD (0.58) | HPGDGAALIPEPOLBALDH1A1 | |
| SCHEMBL18979169 | 0.65 | LMNA (0.34) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220073-B1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA SRL (IT) | 2014-09-03 | — | — | EP | disclosed |
| US-8268827-B2 | Pyridazinone derivatives as PARP inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-09-18 | — | — | US | disclosed |
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | MSD ITALIA S.R.L. (IT) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261709-A1 | PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | HPGD 947/4885GAA 2163/4885LIPE 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.